Literature DB >> 35638051

Evidence-based perioperative diagnosis and management of pulmonary embolism: A systematic review.

Lamesgen Geta Abate1,2, Samuel Debas Bayable1,2, Melaku Bantie Fetene3,2.   

Abstract

Background: The diagnosis and treatment of pulmonary embolism have multi-modal approach based on specificity, sensitivity, availability of the machine, and associated risks of imaging modalities. Aim: This review aimed to provide shreds of evidence that improve perioperative diagnosis and management of suspected pulmonary embolism.
Methods: The study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline 2020. After a clear criteria has been established an electronic searching database was conducted using PubMed, Google Scholar, Cochrane library, and Cumulative Index of Nursing and Allied Health Literature (CINAHL), with Key search terms included:('pulmonary embolism' AND' anesthesia management ', 'anticoagulation' AND 'pulmonary embolism', 'thrombolysis 'AND 'pulmonary embolism', 'surgery' AND' pulmonary embolism'), were used to draw the evidence.The quality of literatures were categorized based on WHO 2011 level of evidence and degree of recommendation, in addition, the study is registered with research registry unique identifying number (UIN) of reviewregistry1318." and has high quality based on AMSTAR2 assessment criteria.
Results: A totally of 27 articles were included [guidelines (n = 3), Cochrane (=5), systemic reviews (n = 7), meta-analyses (=2), RCT (n = 4), cohort studies (n = 3), and cross-sectional study (n = 3) and illegible articles identified from searches of the electronic databases were imported into the ENDNOTE software version X7.1 and duplicates were removed. Discussion: Currently divergent and contradictory approaches are implemented in diagnosis and management for patients suspected of pulmonary embolism.
Conclusion: All perioperative patients, especially trauma victims, prostate or orthopedic surgery, malignancy, immobility, and obesity; smokers; and oral contraceptive users, antipsychotic medications are at increased risk of venous thromboembolism and need special caution during surgery and anesthesia.
© 2022 The Authors.

Entities:  

Keywords:  Anesthesia management; Anticoagulation; CASP, Critical Appraisal Skills Programmed; CTPA, Computed Tomography Pulmonary Angiography; DVT, Deep Venous Thrombosis; PE, Pulmonary Embolism; Pulmonary embolism; Thrombolysis; WHO, World Health Organization

Year:  2022        PMID: 35638051      PMCID: PMC9142630          DOI: 10.1016/j.amsu.2022.103684

Source DB:  PubMed          Journal:  Ann Med Surg (Lond)        ISSN: 2049-0801


Introduction

Pulmonary Embolism(PE) is a treatable illness caused by the migration of thrombi to the pulmonary circulation, from the veins of the lower extremities[[1], [2], [3], [4]], commonly arises from Deep veins of the legs which range from asymptomatic, to massive which results in sudden death[5]. The prevalence of pulmonary embolism in developed countries was about 2.2% [6,7].and in the United States it causes a high rank among cardiovascular mortality[7], while in Africa, it has been reported in 3.8–32.4%, in patients with clinical suspicion of pulmonary embolism(PE) [4], but the incidence of PE increased to fivefold during and after surgery[8]. even though the diagnosis of PE is often obscured intraoperatively with common disorders including bleeding and infection physicians and anesthetists are responsible for the diagnosis and management of such fatal disorders [8]. Pulmonary embolism-associated vasoconstriction, mediated by the release of thromboxane A2 and serotonin, contributes to the initial increase in pulmonary vascular resistance (PVR) after PE. Anatomical obstruction and hypoxic vasoconstriction in the affected lung area lead to an increase in PVR and a proportional decrease in arterial compliance[7, 9]. Helical computed tomography and Transesophageal echocardiography are preferred to diagnose in the operating room for all patients at increased risk of venous thromboembolism, such as trauma victims and those undergoing prostate or orthopedic surgery [6,8]. The initial management of pulmonary embolism may be started before a definitive diagnosis is established, started with supportive treatment followed by vasopressors aimed at stabilizing the patient and minimizing the effect of the embolic occlusion to improve right ventricular function and contract the systemic vasculature to maintain blood pressure respectively[8, 10].

Justification

Pulmonary embolism is a potentially life-threatening condition that needs immediate diagnosis and management [9], since Surgery puts patients at a fivefold increased risk for pulmonary embolism[[7], [8], [9]], in addition, perioperative thromboprophylaxis is underutilization in Ethiopian hospital ward patients who have a risk of pulmonary embolism and professionals do not adhere to guideline recommendations[11]. Even if Pulmonary angiography is the standard for establishing the presence of pulmonary embolism, a negative pulmonary angiogram doesn't rule out pulmonary embolism due to its insufficient sensitivity to detect small emboli [8,9,12]. In addition, D-dimer tests are rapid, simple, inexpensive, and can prevent high costs associated with expensive diagnostic tests [13]. Although pulmonary embolism is a leading cause of death worldwide, controversies' regarding diagnosis, treatment, and follow-up persist, having a wide range of treatment options including anticoagulation alone, catheter-directed thrombolysis, catheter embolectomy, surgical embolectomy, and/or mechanical circulatory support device, so this study helps to develop an institutional working protocol to provide optimal diagnosis and treatment of pulmonary embolism during the perioperative period of high risk and suspected patients.

Objectives

General objective

To improve perioperative diagnosis and management of suspected pulmonary embolism patients.

Specific objectives

To provide a working framework for diagnosis of pulmonary embolism. To prepare pulmonary embolism management protocol.

Methods

The study is conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline 2020 [14] as shown in (Fig. 1). After a clear criteria has been established an electronic database search was conducted using PubMed, Google Scholar, Cochrane Library, Cumulative Index of Nursing and Allied Health Literature (CINAHL), with Key search terms included:(‘pulmonary embolism’ AND′ anesthesia management ‘, ‘anticoagulation’ AND ‘pulmonary embolism’, ‘thrombolysis ‘AND ‘pulmonary embolism’, ‘surgery’ AND’ pulmonary embolism’), were used to draw pieces of evidence. Synonyms and truncations of these keywords were used, and database-specific medical subject headings (MeSH) were also included. The inclusion and exclusion of these studies are stated in (Table 1).
Fig. 1

Flow chart for selection of studies using 2020 PRISMA flow diagram.

Table 1

The inclusion and exclusion criteria of the studies in this review.

Inclusion criteriaExclusion criteria
PopulationSurgical patients at risk of pulmonary embolismSurgical patient having less risk factor for pulmonary embolism
SourcesPublished in peer reviewed JournalsNot published in peer reviewed Journals
Publication datePublished between 2010 and 2022Published prior to 2010
LanguagePublished in EnglishPublished in languages other than English
AvailabilityFull textFull text unavailable
Study designPrimary research that focuses on pulmonary embolismSecondary research
QualityStudies evaluated as moderate or high quality according to the Critical Appraisal Skills Programme checklistsStudies evaluated as low quality according to the Critical Appraisal Skills Programme checklists
Flow chart for selection of studies using 2020 PRISMA flow diagram. Algorithm for patients with suspected high-risk pulmonary embolism presenting with hemodynamic instability. The inclusion and exclusion criteria of the studies in this review. Selection of studies was detailed using PRISMA 2020 flow diagram(14) as shown (Fig. 1).

Data quality appraisal and synthesis

Before inclusion each study in the review of the literature, the quality of each study was assessed by all authors independently using the Critical Appraisal Skills Programme (CASP) checklists [15,16],and authors consulted their findings with each other, then agreed on the final studies to be included in the review. The authors defined moderate and high methodological quality as meeting 60–80% and 90–100% of the CASP checklist criteria respectively [[15], [16], [17]]. The minimum percentage threshold for inclusion in the review of the literature was decided to be 60% of the criteria [17] and uses the WHO 2011 level of evidence and degree of recommendation (Table 2) [18], and this study is registered with a link of https://www.researchregistry.com/browse-the-registry#registryofsystematicreviewsmeta-analyses/with a unique identifying number (UIN) of 1318 and the study has high quality based on AMSTAR 2 quality assessment checklist/https://amstar.ca/Amstar_Checklist.php.
Table 2

WHO 2011 level of evidence and degree of recommendation.

LevelType of evidenceDegree of recommendation
1aMeta-analyses, systematic reviews of RCTsStrongly recommended/directly applicable
1bSystematic reviewHighly recommended/directly applicable
1cRandomized clinical trials/RCTsRecommended/applicable
2aSystematic reviews of case-control or cohort studies.Extrapolated evidence from other studies
3aNon-analytic studies, e.g. case reports, case seriesExtrapolated evidence from other studies
WHO 2011 level of evidence and degree of recommendation.

Results

A summary of the included studies in the review of the literature can be seen in (Table 1). Totally 27 articles were included [guidelines (n = 3), Cochrane (=5), systemic reviews (n = 7), meta-analyses (=2), RCT (n = 4), cohort studies (n = 3), and cross-sectional study (n = 3) which were more updated and focused on pulmonary embolism management. Illegible articles identified from searches of the electronic databases were imported into the ENDNOTE software version X7.1 (Tomson Reuters, USA) and duplicates were removed. Before findings had begun, full-length articles of the selected studies were read to confirm for fulfilling the inclusion criteria.

Discussion

Pulmonary embolism (PE) is a life-threatening condition in which a clot travels from deep veins of the lower extremity to the circulation and lodges into the lungs[7]. Clinical presentation of venous thromboembolism (VTE) is globally the third most frequent acute cardiovascular syndrome behind myocardial infarction and stroke [7]. Human immunodeficiency virus (HIV) increases the risk of PE two-to ten fold as compared with the general population, major surgery, Hip or knee replacement, and General anesthesia when compared with epidural [4,19]. Computed Tomography Pulmonary Angiography (CTPA) has greatly improved the diagnostic approach to patients with suspected PE and is considered to be the reference imaging test, but should be used, with caution in some patients, such as patients with severe renal insufficiency, those with known allergy to contrast media, and pregnant women[[19], [20], [21]]. Additionally, ECG findings include sinus tachycardia, atrial dysrhythmia, dramatic shift in R wave axis, incomplete or complete right bundle-branch block, inferolateral ST-segment elevation, or depression, inversion of T waves in leads V1–V4, and biomarkers such as elevated D-dimers or fibrin degradation are suggestive of PE [9,13,19,22,23]. D-dimer assays can rule out PE. But has low specificity of positive tests, especially in older age groups[13, 24]. If the patient presents with at least three parameters out of the five most common signs and symptoms of PE (cough, hypoxia, dyspnea, tachycardia, and chest pain) with the inclusion of X-ray and echocardiography results it is satisfactory pieces of evidence to make high suspicions of acute pulmonary embolism that requires diagnosis and management at bedside within a few minutes, but if the patient is hemodynamically stable, CTPA can be performed to confirm the diagnosis(12, 25). Acute pulmonary embolism requires anticoagulation to prevent early death and recurrent symptomatic fatal venous thromboembolism. The standard duration of anticoagulation cover at least 3 months and parenteral anticoagulation [unfractionated heparin, low molecular weight heparin, or fondaparinux] over the first 5–10 days should be given to treat acute PE [7,19,24,26,27]. Hypoxaemia is one feature of severe PE and resulted from the mismatch between ventilation and perfusion, so supplemental oxygen is required in patients' level of SpaO2 <90%. Patients with right ventricular failure are highly susceptible to the development of severe hypotension during induction of anesthesia, intubation, and positive-pressure ventilation [7]. Thrombolytic therapy is associated with a significant reduction in overall mortality, pulmonary embolism recurrence as compared with heparin, but increased intracranial hemorrhage and is not significant in hemodynamically stable patients [8,10,19,28,29]. Hemodynamically deteriorating suspected pulmonary embolism patients require rescue thrombolytic therapy, in addition, surgical embolectomy and catheter-directed treatment are alternatives to the treatment of pulmonary embolism to rescue thrombolytic therapy [7,9,19,24]. Intravenous catheter filters reduce the risk of subsequent pulmonary embolism, increase the risk of DVT, and have no significant effect on overall mortality, so Intravenous catheter (IVC) filters should be considered for limited scenarios, such as contraindication to antithrombotic therapy or recurrent pulmonary embolism despite adequate anticoagulation[7, 30]. A fixed-dose regimen of rivaroxaban is as effective as standard anticoagulant therapy for the treatment of DVT prophylaxis, without the need for laboratory monitoring[28, 31]. Deep venous thrombosis (DVT) can be prevented through non-pharmacologic prophylaxis (compression stockings, leg elevation, sequential compression devices (SCDs), ambulation, and vena cava filter) and pharmacologic intervention, which is through the use of blood-thinning medications[2, 11, 27]. The most common blood thinner prophylaxis in Ethiopia is unfractionated heparin (UFH) and warfarin. The major side effect of blood-thinning medications is an increased risk of bleeding and some patients are contraindicated for blood-thinning medications since they have a greater risk of developing adverse events[11, 24]. The overall mortality rate in untreated patients is 30%, with approximately 10% of patients dying within 1 h of the event. Haemodynamically unstable patients have the highest mortality rate, which can be as high as 58% [4,7,32]. Generally the overall summary for patients with suspected high-risk pulmonary embolism presenting with hemodynamic stable and instable patients are detailed as shown in (Fig. 2 and Fig. 3) respectively.
Fig. 2

Algorithm for patients with suspected high-risk pulmonary embolism presenting with hemodynamic instability.

Fig. 3

Algorithm for patients with suspected pulmonary embolism without hemodynamic instability.

Algorithm for patients with suspected pulmonary embolism without hemodynamic instability.

Conclusion

All perioperative patients, especially trauma victims, prostate or orthopedic surgery, malignancy, immobility, and obesity; smokers; and oral contraceptive users, antipsychotic medications are at increased risk of venous thromboembolism and need special caution during surgery and anesthesia.

Authors contribution

•Lamesgen Geta Abate = study concept or design, litreture review, data cleaning, and data interpretation. •Samuel Debas Bayable = litreture review, data cleaning, and data interpretation, manuscript wrting •Melaku Bantie Fetene = Check grammer and plagiarism,corrected flow of ideas.

Registration of research studies

1. Name of the registry: Research studies. 2. Unique Identifying number or registration ID: 1318. 3. Hyperlink to your specific registration (must be publicly accessible and will be checked): researchregistry1318”.

Guarantor

Samuel Debas Bayable, and Lamesgen Geta Abate.

Ethics approval and consent to participate

Ethical approval was granted with Debre Markos University School of Medicine.

Availability of data and materials

Data and materials are fully available without restriction and present upon request.

Funding

The authors received no financial support for the research authorship/or publication of this article.

Consent

Not required.

Provenance and peer review

All authors were equally participated to address Comments and suplimented in the manuscript before sending the revised form for publication. Not commissioned, externally peer, reviewer. Kokeb Desta (Asst.prof. in Advanced Clinical Anesthesia) kokeb.desta@gmail.com helps us in method of reviewing and overall writings in spelling, grammar and punctuation.

Declaration of competing interest

The authors declare that there is no conflict of interest.
  29 in total

Review 1.  Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association.

Authors:  J Hirsh; J Hoak
Journal:  Circulation       Date:  1996-06-15       Impact factor: 29.690

2.  Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

Authors:  Harry R Büller; Martin H Prins; Anthonie W A Lensin; Hervé Decousus; Barry F Jacobson; Erich Minar; Jaromir Chlumsky; Peter Verhamme; Phil Wells; Giancarlo Agnelli; Alexander Cohen; Scott D Berkowitz; Henri Bounameaux; Bruce L Davidson; Frank Misselwitz; Alex S Gallus; Gary E Raskob; Sebastian Schellong; Annelise Segers
Journal:  N Engl J Med       Date:  2012-03-26       Impact factor: 91.245

Review 3.  Medical emergencies: pulmonary embolism and acute severe asthma.

Authors:  K Somasundaram; J Ball
Journal:  Anaesthesia       Date:  2013-01       Impact factor: 6.955

Review 4.  The diagnosis and treatment of acute pulmonary embolism.

Authors:  Alexander Schellhaass; Andreas Walther; Stavros Konstantinides; Bernd W Böttiger
Journal:  Dtsch Arztebl Int       Date:  2010-08-30       Impact factor: 5.594

5.  Recommendations for the diagnosis and treatment of deep venous thrombosis and pulmonary embolism in pregnancy and the postpartum period.

Authors:  Claire McLintock; Tim Brighton; Sanjeev Chunilal; Gus Dekker; Nolan McDonnell; Simon McRae; Peter Muller; Huyen Tran; Barry N J Walters; Laura Young
Journal:  Aust N Z J Obstet Gynaecol       Date:  2011-10-06       Impact factor: 2.100

6.  Advances in the diagnosis and treatment of acute pulmonary embolism.

Authors:  Victor F Tapson
Journal:  F1000 Med Rep       Date:  2012-05-02

7.  2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS).

Authors:  Stavros V Konstantinides; Guy Meyer; Cecilia Becattini; Héctor Bueno; Geert-Jan Geersing; Veli-Pekka Harjola; Menno V Huisman; Marc Humbert; Catriona Sian Jennings; David Jiménez; Nils Kucher; Irene Marthe Lang; Mareike Lankeit; Roberto Lorusso; Lucia Mazzolai; Nicolas Meneveau; Fionnuala Ní Áinle; Paolo Prandoni; Piotr Pruszczyk; Marc Righini; Adam Torbicki; Eric Van Belle; José Luis Zamorano
Journal:  Eur Heart J       Date:  2020-01-21       Impact factor: 35.855

8.  The prevalence and radiological findings of pulmonary embolism in HIV-positive patients referred for computed tomography pulmonary angiography in the Western Cape of South Africa.

Authors:  Raksha Ramlakhan; Savvas Andronikou; Ashmitha Rajkumar
Journal:  Cardiovasc J Afr       Date:  2017-02-15       Impact factor: 1.167

9.  EANM guideline for ventilation/perfusion single-photon emission computed tomography (SPECT) for diagnosis of pulmonary embolism and beyond.

Authors:  Marika Bajc; Carl Schümichen; Thomas Grüning; Ari Lindqvist; Pierre-Yves Le Roux; Adriano Alatri; Ralf W Bauer; Mirza Dilic; Brian Neilly; Hein J Verberne; Roberto C Delgado Bolton; Bjorn Jonson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-13       Impact factor: 9.236

Review 10.  Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis.

Authors:  Christophe Marti; Gregor John; Stavros Konstantinides; Christophe Combescure; Olivier Sanchez; Mareike Lankeit; Guy Meyer; Arnaud Perrier
Journal:  Eur Heart J       Date:  2014-06-10       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.